Breaking Finance News

Microbot Medical Inc (NASDAQ:MBOT) has been upgraded to Sell in a statement by ValuEngine earlier today.

ValuEngine has upgraded Microbot Medical Inc (NASDAQ:MBOT) to Sell in a statement released on 6/02/2017.

Having a price of $3.81, Microbot Medical Inc (NASDAQ:MBOT) traded 1.71% higher on the day. With the last close up -47.87% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the same period. Microbot Medical Inc has recorded a 50-day average of $1.21 and a two hundred day average of $2.28. Volume of trade was down over the average, with 628,148 shares of MBOT changing hands under the typical 1,565,400

Performance Chart

Microbot Medical Inc (NASDAQ:MBOT)

With a total market value of $0, Microbot Medical Inc has with a one year low of $1.00 and a one year high of $15.66 .

More About Microbot Medical Inc (NASDAQ:MBOT)

Microbot Medical Inc., formerly StemCells, Inc., is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures. Its ViRob technology is an autonomous crawling micro-robot, which can be controlled remotely or within the body. The Microbot SCS device is a robotic system designed as the ventricular catheter portion of a cerebrospinal fluid (CSF) shunt system. The Company's TipCAT is an endoscope that provides see and treat capabilities within tubular lumens in the human body, such as the colon, blood vessels and the urinary tract.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.